Lilly to acquire Orna Therapeutics for up to $2.4 billion
Lilly's up-to-$2.4 billion purchase of Orna buys a platform for making CAR-T cell therapies inside the body, but no human results or trial start dates have been reported [1].
Eli Lilly has agreed to acquire Orna Therapeutics, a Watertown, Massachusetts biotechnology company, in a cash deal worth up to $2.4 billion, the companies announced on Feb. 9, 2026 [1]. Orna is developing a way to make cell therapies inside a patient's body instead of removing immune cells, engineering them in a lab and putting them back [1].
Orna's approach pairs engineered circular RNA with lipid nanoparticles, the fatty delivery particles also used in some mRNA vaccines, to instruct a patient's own cells to produce a therapy [1]. Its lead program, ORN-252, is a CD19-targeting in vivo CAR-T therapy that the company describes as clinical trial-ready and designed to treat B cell-driven autoimmune diseases [1]. CD19 is a marker on the surface of B cells, the immune cells involved in those conditions [1].
Experiments to date suggest the circular RNA platform may deliver more durable expression of therapeutic proteins, which the company says could unlock treatments that are not feasible with current RNA or cell therapy platforms [1]. Orna states that its circular RNA transcripts offer advantages over traditional mRNA, including simplified production, improved formulation into lipid nanoparticles, and superior protein expression [1].
"Early autologous CAR-T studies have shown the promise of cell therapy for patients with autoimmune diseases, but the complexity, cost, and logistics of ex vivo approaches make it challenging to deliver these breakthroughs to the broader population of patients who need them," said Francisco Ramírez-Valle, M.D., Ph.D., Lilly's senior vice president and head of immunology research and early clinical development [1]. "We look forward to working with Orna colleagues to potentially unlock an entirely new class of genetic medicines and cell therapies for patients who today have limited or no treatment options" [1].
Joe Bolen, Ph.D., Orna's chief executive officer, said the company believes its circular RNA technology and lipid nanoparticle delivery platform could unlock in vivo CAR-T therapies "for patients across a wide range of B cell-driven autoimmune diseases" [1].
Under the agreement, Orna shareholders could receive up to $2.4 billion in cash, inclusive of an upfront payment and later payments tied to clinical development milestones [1]. Lilly said it will determine the accounting treatment of the transaction in line with Generally Accepted Accounting Principles once it closes [1]. Lazard is financial advisor to Orna, and Goodwin Procter LLP is its legal counsel; Paul, Weiss, Rifkind, Wharton & Garrison LLP is legal counsel to Lilly [1]. Lilly also cautioned that it cannot guarantee the acquisition will achieve the results described or yield commercially successful products [1].
Why it matters for patients
ORNA-252 is not a GLP-1 medicine, and the announcement does not mention tirzepatide (sold as Mounjaro and Zepbound), semaglutide, or orforglipron [1]. The acquisition does not change how any currently marketed medicine is prescribed, covered, or priced, and the companies described no effect on Lilly's existing products [1].
If in vivo CAR-T works as hoped, it would replace a process in which a patient's cells are collected, genetically altered outside the body, and reinfused. Lilly's immunology research chief cited the "complexity, cost, and logistics" of that ex vivo approach as a barrier to reaching more patients [1]. No human results for ORN-252 have been reported in the announcement, and the company calls the program clinical trial-ready rather than in trials, so any patient benefit is unproven [1]. The announcement also does not say whether the technology could apply to obesity, diabetes, or other conditions outside B cell-driven autoimmune disease [1].
The purchase is part of a broader Lilly pipeline that the company's incretin medicines — its GLP-1 and related obesity and diabetes drugs — are helping to fund [2].
What happens next
Orna shareholders receive an upfront cash payment plus additional payments if certain clinical development milestones are met; the amounts of those milestones and their timing were not disclosed [1]. Lilly did not disclose when the deal is expected to close or what conditions remain, and no start date for an ORN-252 clinical trial was given [1]. The release states only that early autologous CAR-T studies have shown promise, without citing specific data [1].
Sources
Semaglutides.org provides information only, not medical advice. Talk to a licensed provider about your own care before making changes. Some telehealth links are affiliate links and are labeled where they appear.